RPL22 Mutations May Shape Drug Sensitivity in Aggressive Endometrial Cancer
Researchers found RPL22 mutations in 42% of undifferentiated/dedifferentiated endometrial carcinoma samples and showed in cell and xenograft models that the ...
Researchers found RPL22 mutations in 42% of undifferentiated/dedifferentiated endometrial carcinoma samples and showed in cell and xenograft models that the ...
A new clinical mini-review proposes an evidence-informed framework for deciding which bladder cancer patients should be evaluated for previously unrecognized ...
A case report documents four metachronous neoplasms in one MSH2 mutation carrier over eight years, with only the endometrial cancer ...
Mouse experiments show that CD4+ T cells license CD8+ T cells through CD40 signaling, enabling combination immunotherapy to eliminate mismatch ...
In a 108-patient tissue study, mismatch repair deficiency was absent from bladder urothelial carcinoma cases and stable across paired specimens, ...
Long-term results from the phase 2 NICHE-2 trial show that none of 111 patients with dMMR colon cancer treated with ...
A FAIR²-certified dataset from a single Chinese hospital documents mismatch repair and microsatellite instability status, tumor sites, histology, and comorbidities ...
A detailed case report from China shows that a rare non-hotspot POLE p.T278K mutation, alongside dual MSH6 frameshift variants and ...
Bridging studies confirm that the Ventana MMR RxDx Panel and FoundationOne CDx reliably identify dMMR/MSI-H tumor patients likely to respond ...
Mathematical modelling shows that elevated mutation rates and mutational biases, rather than altered selection, can explain why weak atypical KRAS ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine